We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

6 hedge funds and large institutions have $550K invested in ProShares UltraShort NASDAQ Biotechnology in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

2.45% less ownership

Funds ownership: 10.06% → 7.61% (-2.5%)

45% less capital invested

Capital invested by funds: $992K → $550K (-$442K)

83% less call options, than puts

Call options by funds: $4K | Put options by funds: $23K

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
1
Calls
$4K
Puts
$23K
Net Calls
-$19K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
IMC Chicago
IMC Chicago
Illinois
+$342K
2
UBS Group
UBS Group
Switzerland
+$6.11K
3
Morgan Stanley
Morgan Stanley
New York
+$4.6K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$281K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$259K
3
TRCT
Tower Research Capital (TRC)
New York
-$123K
Name Holding Trade Value Shares
Change 		Change in
Stake
IMC Chicago
1
IMC Chicago
Illinois
$271K +$342K +7,501 New
Citadel Advisors
2
Citadel Advisors
Florida
$181K -$281K -6,169 -55%
TRCT
3
Tower Research Capital (TRC)
New York
$85.3K -$123K -2,702 -53%
Morgan Stanley
4
Morgan Stanley
New York
$5.85K +$4.6K +101 +166%
UBS Group
5
UBS Group
Switzerland
$4.93K +$6.11K +134 +4,467%
Citigroup
6
Citigroup
New York
$1.54K – – –
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
– -$259K -5,786 Closed

BIS Hedge Fund Activity: Q4 2023 in Review

6 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2023, worth a combined $550K — down 45% from $992K a quarter earlier.

Fund positioning in BIS was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was IMC Chicago, opening a new position worth an estimated $342K. The largest seller was Citadel Advisors, cutting an estimated $281K.

  • 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $550K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2023, down 45% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2023 and 1 closed out, a net change of 0 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2023 was IMC Chicago, an estimated $342K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2023 was Citadel Advisors, an estimated $281K sold.

Based on aggregated 13F filings for Q4 2023.